Optimization of Docetaxel Loading Conditions in Liposomes: Proposing Potential Products for Metastatic Breast Carcinoma Chemotherapy

Overview

Journal Sci Rep

Specialty Science

Date 2020 Mar 30

PMID 32221371

Citations 21

Authors

Roghayyeh Vakili-Ghartavol

Seyed Mahdi Rezayat

Reza Faridi-Majidi

Kayvan Sadri

Mahmoud Reza Jaafari

Affiliations

Soon will be listed here.

Abstract

Docetaxel (DTX) was loaded in nanoliposomes based on a new remote loading method using mannitol and acetic acid as hydration buffer. DTX loading conditions were optimized, and the final formulations were prepared according to the best parameters which were HSPC/mPEG2000-DSPE/Chol (F1), HSPC/mPEG2000-DSPE/DPPG/Chol (F2), HSPC/mPEG2000-DSPE/DSPG/Chol (F3), at molar ratios of 85/5/10, 80/5/5/10, 80/5/5/10, respectively. DTX-liposomes were found of desired size (~115 nm) and homogeneity (PDI ≤ 0.2), high drug encapsulation efficacy (34-67%) and DTX concentration, and favorable stability. Passive loaded counterparts liposomes showed three times lower encapsulation efficacy compared to the remote loaded liposomes. The drug release of remote loaded liposomes in plasma 50% was significantly more controlled and less in comparison with their passive loaded counterparts (p < 0.0001). The IC50 values of formulations were determined on MCF-7, 4T1, TUBO, NIH/3T3 cell lines. The biodistribution of iodinated docetaxel as free or liposomal form exhibited significantly greater accumulation of DTX-liposomes in tumors than that of free docetaxel due to the EPR effect. In vivo experiment with BALB/c mice bearing 4T1 or TUBO breast carcinoma tumors also showed that DTX-liposomes could significantly delay tumor growth and prolonged the survival time in comparison with control and Taxotere groups at the similar dose of 8 mg/kg. F1 and F2 formulations were stable and showed good anti-tumor activity and merit further investigation.

Citing Articles

PEGylated Nanoliposomes Encapsulated with Anticancer Drugs for Breast and Prostate Cancer Therapy: An Update.

Peter S, Khwaza V, Alven S, Naki T, Aderibigbe B Pharmaceutics. 2025; 17(2).

PMID: 40006557 PMC: 11859135. DOI: 10.3390/pharmaceutics17020190.

Liposomal Formulations: A Recent Update.

Agrawal S, Baliga V, Londhe V Pharmaceutics. 2025; 17(1).

PMID: 39861685 PMC: 11769406. DOI: 10.3390/pharmaceutics17010036.

Impact of Pluronic F-127 on the Stability of Quercetin-Loaded Liposomes: Insights from DSC Preformulation Studies.

Kosti E, Sotiropoulou H, Tsichlis I, Tsakiri M, Naziris N, Demetzos C Materials (Basel). 2024; 17(22).

PMID: 39597287 PMC: 11595950. DOI: 10.3390/ma17225454.

Potential of Exosomes as Multifunctional Nanocarriers for Targeted Drug Delivery.

Al-Ani S, Lee Q, Maheswaran D, Sin Y, Loh J, Foo J Mol Biotechnol. 2024; .

PMID: 39269575 DOI: 10.1007/s12033-024-01268-6.

Doxorubicin loaded thermostable nanoarchaeosomes: a next-generation drug carrier for breast cancer therapeutics.

Babunagappan K, Seetharaman A, Ariraman S, Santhosh P, Genova J, Poklar Ulrih N Nanoscale Adv. 2024; 6(8):2026-2037.

PMID: 38633044 PMC: 11019490. DOI: 10.1039/d3na00953j.

References

Chen J, Yang Y, Chen T, Lai J, Chang S, Chang C . Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal Doxorubicin (lipo-dox). Taiwan J Obstet Gynecol. 2008; 47(3):322-6. DOI: 10.1016/S1028-4559(08)60132-1. View

Torchilin V . Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014; 13(11):813-27. PMC: 4489143. DOI: 10.1038/nrd4333. View

Wang A, Langer R, Farokhzad O . Nanoparticle delivery of cancer drugs. Annu Rev Med. 2011; 63:185-98. DOI: 10.1146/annurev-med-040210-162544. View

Ahmad I, Allen T . Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 1992; 52(17):4817-20. View

Ahmad I, Longenecker M, Samuel J, Allen T . Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 1993; 53(7):1484-8. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Ernsting M, Murakami M, Roy A, Li S . Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013; 172(3):782-94. PMC: 3891171. DOI: 10.1016/j.jconrel.2013.09.013. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Tuscano J, Martin S, Ma Y, Zamboni W, ODonnell R . Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010; 16(10):2760-8. DOI: 10.1158/1078-0432.CCR-09-3199. View

10.

Gu Z, Wang Q, Shi Y, Huang Y, Zhang J, Zhang X . Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J Control Release. 2018; 286:369-380. DOI: 10.1016/j.jconrel.2018.08.011. View

11.

Chang H, Yeh M . Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012; 7:49-60. PMC: 3260950. DOI: 10.2147/IJN.S26766. View

12.

Zhang W, Wang G, Falconer J, Baguley B, Shaw J, Liu J . Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharm Res. 2014; 32(4):1451-61. DOI: 10.1007/s11095-014-1551-8. View

13.

Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

14.

Hengst V, Oussoren C, Kissel T, Storm G . Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm. 2006; 331(2):224-7. DOI: 10.1016/j.ijpharm.2006.11.024. View

15.

Allen T, Martin F . Advantages of liposomal delivery systems for anthracyclines. Semin Oncol. 2005; 31(6 Suppl 13):5-15. DOI: 10.1053/j.seminoncol.2004.08.001. View

16.

Pattni B, Chupin V, Torchilin V . New Developments in Liposomal Drug Delivery. Chem Rev. 2015; 115(19):10938-66. DOI: 10.1021/acs.chemrev.5b00046. View

17.

Yuan F, Dellian M, Fukumura D, Leunig M, Berk D, Torchilin V . Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55(17):3752-6. View

18.

Cern A, Marcus D, Tropsha A, Barenholz Y, Goldblum A . New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage. J Control Release. 2017; 252:18-27. DOI: 10.1016/j.jconrel.2017.02.015. View

19.

Megha , Sawatzki P, Kolter T, Bittman R, London E . Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts). Biochim Biophys Acta. 2007; 1768(9):2205-12. PMC: 2077851. DOI: 10.1016/j.bbamem.2007.05.007. View

20.

Shao X, Wei X, Zhang S, Fu N, Lin Y, Cai X . Effects of Micro-environmental pH of Liposome on Chemical Stability of Loaded Drug. Nanoscale Res Lett. 2017; 12(1):504. PMC: 6890883. DOI: 10.1186/s11671-017-2256-9. View